S.E. Greasley

Pfizer (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

29h-index3.6kcitations59works19.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Biochemical and Molecular Research(19), Enzyme Structure and Function(10), SARS-CoV-2 and COVID-19 Research(7), PI3K/AKT/mTOR signaling in cancer(7), Computational Drug Discovery Methods(6)

Publications58 total

Abstract C029: PF-07248144 – First-in-class potent, selective KAT6i in ER+HER2− breast cancer
Molecular Cancer Therapeutics·2025
Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main Protease
Journal of Medicinal Chemistry·2025· 15 cited
Modulation of the substrate preference of a MYST acetyltransferase by a scaffold protein
Journal of Biological Chemistry·2025· 3 citedOpen Access
Discovery of Highly Selective Inhibitors of Microtubule-Associated Serine/Threonine Kinase-like (MASTL)
Journal of Medicinal Chemistry·2024· 4 cited
In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance
Science Advances·2024· 34 citedOpen Access
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19
Journal of Medicinal Chemistry·2024· 59 citedOpen Access
Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer
Cell chemical biology·2023· 59 citedOpen Access
Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants
Journal of Biological Chemistry·2022· 168 citedOpen Access
Structural basis for Nirmatrelvir in vitro efficacy against SARS-CoV-2 variants
2022· 26 citedOpen Access
An oral SARS-CoV-2 M <sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19
Science·2021· 1.8k citedOpen Access
An Oral SARS-CoV-2 M <sup>pro</sup> Inhibitor Clinical Candidate for the Treatment of COVID-19
2021· 23 citedOpen Access
Abstract 330: Engineering electrophile-sensitive kinase mutants to accelerate oncology target validation
Cancer Research·2021
Characterization of Specific <i>N</i> -α-Acetyltransferase 50 (Naa50) Inhibitors Identified Using a DNA Encoded Library
ACS Medicinal Chemistry Letters·2020· 34 citedOpen Access
Crystal structure of human Naa50 in complex with a truncated cofactor derived inhibitor (compound 2)
2020
Crystal structure of human Naa50 in complex with an inhibitor (compound 3) identified using DNA encoded library technology
2020
Crystal structure of human Naa50 in complex with a cofactor derived inhibitor (compound 1)
2020
Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain
Journal of Medicinal Chemistry·2018· 35 citedOpen Access
Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors
Journal of Medicinal Chemistry·2018· 52 citedOpen Access
Crystal structure of Tyrosine-protein kinase receptor
2018
Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1<i>H</i>-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate
Journal of Medicinal Chemistry·2017· 134 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Rose Ann Ferre(16), Ian A. Wilson(14), Stephen Noell(7), Claire M. Steppan(7), G. Peter Beardsley(7), Chuangxing Guo(6), Martha A. Ornelas(6), Charlotte Allerton(5), Rhonda D. Cardin(5), K. Devendra(5), Al Stewart(5), Qingyi Yang(5), Yuao Zhu(5), Karen A. Maegley(5), Paul Richardson(5), Dale L. Boger(5), Dafydd R. Owen(4), Annaliesa S. Anderson(4), Lisa Aschenbrenner(4), Melissa Avery(4)